Ventracor Chief Executive Officer Peter Crosby spoke at the 19th...

Ventracor Chief Executive Officer Peter Crosby spoke at the 19th Annual Piper Jaffray Global Health Care Conference on Tuesday 27 November in New York City.

Overall I was happy with the news. Here are some of the negatives and positives;

# Negative:

- cash burn is $2.6 mil / mth, but he said this figure will grow in fiscal yr 08 due to clinical trials being ramped up. However will then ramp down again as revenues increase.

# Positives:

- Opened up the 1st Asian Centre and they expect to implant very soon!!

- Cash bal end of Jun 07 was $48.5 mil(cashed up)

- Innovative US clinical trials which is subject to a Patent which was filed last year which will give VCR a competitive advantage with reference to enrolment / speed / FDA approval much sooner than it will take Thoratec to attain it.

- Implants of 300 to 400 by mid 08 !!!